bioAffinity Technologies (BIAF) EBIAT (2022 - 2025)
Historic EBIAT for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$5.1 million.
- bioAffinity Technologies' EBIAT fell 15244.82% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.7 million, marking a year-over-year decrease of 7450.88%. This contributed to the annual value of -$9.0 million for FY2024, which is 1389.47% down from last year.
- Per bioAffinity Technologies' latest filing, its EBIAT stood at -$5.1 million for Q3 2025, which was down 15244.82% from -$4.1 million recorded in Q2 2025.
- Over the past 5 years, bioAffinity Technologies' EBIAT peaked at -$88052.0 during Q2 2022, and registered a low of -$5.1 million during Q3 2025.
- Its 4-year average for EBIAT is -$2.5 million, with a median of -$2.1 million in 2024.
- Within the past 5 years, the most significant YoY rise in bioAffinity Technologies' EBIAT was 5343.22% (2023), while the steepest drop was 187630.15% (2023).
- Quarter analysis of 4 years shows bioAffinity Technologies' EBIAT stood at -$1.7 million in 2022, then crashed by 41.72% to -$2.4 million in 2023, then decreased by 25.02% to -$3.0 million in 2024, then tumbled by 70.25% to -$5.1 million in 2025.
- Its EBIAT stands at -$5.1 million for Q3 2025, versus -$4.1 million for Q2 2025 and -$2.7 million for Q1 2025.